<DOC>
	<DOCNO>NCT00077766</DOCNO>
	<brief_summary>This study ass efficacy safety intravenous ( iv ) Mircera give maintenance treatment renal anemia chronic kidney disease patient dialysis previously receive iv darbepoetin alfa . The anticipated time study treatment 1-2 year target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Treatment Anemia Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic renal anemia ; dialysis therapy least 12 week screen ; receive darbepoetin alfa iv least 8 week screen . woman pregnant , breastfeed use unreliable birth control method ; administration another investigational drug within 4 week screening , study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>